PICKERING GRANT sold $1.2M of PCVX
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 22,237 shares of Vaxcyte, Inc. (PCVX) at an average of $55.21 ($54.28–$56.12, $1.23M total) across 3 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale totals ~$1.23M across three trades at ~$54.28–$56.12/share, with a stated pre-arranged 10b5-1 plan.
Market read
This provides a fresh, primary-source datapoint on insider selling, but the 10b5-1 framing limits fundamental interpretation.
What to watch
The filing does not disclose reasons for sale; traders should compare with prior insider activity and the company’s upcoming catalysts (earnings/clinical updates) rather than over-weighting this single transaction.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
SEC Form 4 shows Vaxcyte CEO Pickering Grant sold 22,237 shares in open-market trades for ~$1.23M on 2026-06-26.
Likely limited near-term impact; any effect is more sentiment/positioning than new fundamentals.
The filing is primary-source and same-day, but it explicitly cites a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPickering Grant
CEO and director who sold shares in open-market trades.
